Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 15 of 15 for “"HER2+ breast cancer"”.
-
Anti-Insulin Resistance Treatments Suppress Her2+ Breast Cancer Growth Via Altering Metabolism
… a significant risk factor for carcinogenesis and cancer death, including breast cancer. Our previous finding in patients showed that anti-insulin resistance treatments are associated with improved HER2<sup>+</sup> breast cancer survival of diabetic women. However, there were no transgenic mouse …
-
INVESTIGATION OF LIGAND SIZE ON TARGETED PLGA NANOPARTICLES FOR HER2 BREAST CANCER: TRASTUZUMAB AND ITS ScFv ANTI-HER2 ANTIBODY
… human epidermal growth factor receptor-2 (HER2) specifically in breast cancer. Poly (D, L-lactide-co-glycolide) (PLGA) polymer, which is approved by FDA, was used to form nanoparticles (NPs) encapsulating docetaxel (DOC) as chemotherapy. HER2 antibody moieties, either whole IgG (TrAb) or …
-
A proteomics study to investigate the role of the neural niche in the development of metastatic HER2+ breast cancer
… immunocompetent lodging spot for the circulating cancer cells. Therefore, it is a "popular" destination for metastasized cancers which even surpass the incidents of primary brain tumors. It is hypothesized that the disseminated cancer cells engage with the host cells of the perivascular neural …
-
Integrin-Mediated Mechanotransduction Controls Activation of Yap and Invasive Growth of Breast Cancer
… is correlated with the aggressiveness of breast cancer. Integrin-mediated adhesion and signaling are crucial for mammary tumorigenesis and tumor progression, in which focal adhesion kinase (FAK) - Src family kinases (SFKs) serves as a hub to relay the mechanical cues from the ECM. We have …
-
The Development of Novel Radioimmunoconjugates for the PET Imaging and Radioimmunotherapy of Cancer
… for visualizing HER2+ breast cancer. Further, we introduce a new mAb with a catalytic domain that allows for the site-selective bioconjugation of chelators to yield [<sup>177</sup>Lu]Lu-CHX-A”-DTPA-PODS-HER2DVD for targeting HER2+ breast cancer. For immunoPET, …
-
ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.
… and trastuzumab emtansine (T-DM1) are anti-HER2 antibody-drug conjugates (ADCs) which have shown robust efficacy for treating breast cancer. For both ADCs, however, we lack effective biomarkers to predict outcomes from pre-treatment samples. Methods: To unveil predictive biomarkers for ADCs, …
-
Integrating Functional Genomics with Systems Biology to Discover Drivers and Therapeutic Targets of Human Malignancies
… functional RNAi screens with systems biology of cancer genomics to tailor potential therapeutics for reversal of drug-resistance or treatment of aggressive tumors. I developed a series of algorithms and tools to deconvolute, QC and post-analyze high-throughput shRNA screening data by …
-
Prevalence of Pik3ca-Mutations and Response to First-Line Endocrine Therapy in a Population of Bulgarian Patients with HR(+) HER2(–) Metastatic Breast Cancer // Честотата на PIK3CA-мутацията и отговорът към първа линия ендокринна терапия в популацията от български пациентки с HR(+)HER2(-) метастазирал карцином на гърдата
… examined 250 patients with metastatic HR(+)/HER2(–) breast cancer, diagnosed and treated between January 2016 and November 2022 at three hospitals in Bulgaria (Nadezhda Hospital - Sofia, St. Marina University Hospital – Varna, Acibadem City Clinic Hospital Tokuda – Sofia). The prevalence of …
-
Pi3K- and Mtor-Dependent Mechanisms of Lapatinib Resistance and Resulting Therapeutic Opportunities
<p>Breast cancers with HER2 amplification represent 20-25% of breast cancer cases and are frequently responsive to the HER2 kinase inhibitor lapatinib, but generally for only short duration. We aimed to understand how breast cancers with HER2 amplification become resistant to lapatinib, in order to …
-
The Addition of Melatonin to 17beta-Estradiol and Progesterone Modulated Markers Relevant to Mammary Tumor Development and Modulated Steroid Receptors Relevant to Uterine Protection in a Mouse Model of Breast Cancer
… HRT use declined after an increased risk of breast cancer was reported by the Women's Health Initiative. With the ultimate goal of developing a novel replacement therapy to relieve menopausal symptoms without increasing the risk of breast cancer, we postulated that a novel replacement therapy …
-
NF1 AS A REGULATOR OF CYTOSKELETON DYNAMICS AND BIOMARKER FOR DECISION-MAKING IN HER2-POSITIVE BREAST CANCER
… mutated gene between metastatic and primary HER2+ breast cancer (BC), so we investigated the biological consequences of NF1 loss on sensitivity to antineoplastic treatment and on the metastatic process. We generated NF1 knockout (KO) HER2+ BC cells (i.e.: BT-474, SK-BR-3, HCC1954) by …
-
p,p' DDE Regulated Gene Expression and Possible Mechanisms of Action in Breast Tumor
… has been speculated to increase breast cancer risk due to its environmental persistence, levels of bioaccumulation in breast adipose tissue, and endocrine disrupting actions. Epidemiological studies have had inconsistent findings, however a study in MMTV-neu mice determined that …
-
Rerouting Pre-Existing Host Vaccine-Induced Immunity to wards Breast Cancer
… to activate the immune system to prevent cancer metastasis or recurrence; however, owing to host immune tolerance to cancer antigens and the immunosuppressive environment at tumor sites, many such attempts have failed. The recent success of anti-CTLA4, PD-L1 and PD-1 antibodies targeting …
-
Identification of substrate-selective histone deacetylases and their inhibitors that mediate HER2 transcript stability
<p>Breast cancer is the most common malignancy diagnosed in women. 15-20% of these cancers overexpress the HER2 (ERRB2) oncoprotein. HER2-positive breast cancers are generally aggressive and are associated with poor prognosis. Unfortunately, only a mere 30% of HER2-positve patients respond to …
-
Costo-efectividad de la biopsia líquida para definir cambio farmacológico en cáncer de mama HER2 + avanzado en Colombia
… costos para los sistemas de salud. El subtipo HER2 +, representa el 30% del cáncer de mama y es considerado de mal pronóstico. Las terapias anti-HER2 presentan resistencia requiriendo cambio en las líneas de tratamiento. La biopsia líquida es una técnica poco invasiva, de fácil acceso y con …